Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + ribavirin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Peginterferon alfa-2b + ribavirin is a combination therapy used primarily for the treatment of chronic hepatitis C infection in adults and children who show signs of liver damage and have not previously been treated with interferons. Peginterferon alfa-2b is a synthetic, recombinant form of human interferon conjugated to polyethylene glycol, which prolongs its activity in the body. It acts by binding to type 1 interferon receptors, activating the JAK/STAT pathway and inducing antiviral gene expression. Ribavirin is a nucleoside analogue prodrug that inhibits viral RNA synthesis through multiple mechanisms, including inhibition of inosine monophosphate dehydrogenase (IMPDH), depletion of GTP pools, direct mutagenesis leading to 'error catastrophe' in viral replication, and immunomodulatory effects favoring Th1 immune responses. The combination enhances antiviral efficacy against hepatitis C virus (HCV). Peginterferon alfa-2b has also been used as adjuvant therapy for malignant melanoma after surgical resection[1][3][6][8].
- Brand names
- PEG-IntronPeg Intron RPSylatron
- Other names
- peginterferon alpha 2b + ribavirin
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on peginterferon alfa-2b + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + ribavirin.